Left ventricular diastolic dysfunction induced by cyclophosphamide in blood stem cell transplantation

Tadashi Mori, Nobuhito Yanagi, Toru Maruyama, Hisashi Gondo, Takashi Okamura, Yoshikazu Kaji, Mine Harada

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Cardiac complications are major limiting factors regarding the success of high-dose chemotherapy supported by blood stem cell transplantation (BSCT). The cardiotoxicity of cyclophosphamide remains obscure relative to that of anthracyclines. The aim of this study was to estimate noninvasively the cardiotoxicity of cyclophosphamide administered during the pretransplant conditioning of BSCT for patients with various hematological diseases. A total of 27 consecutive patients were divided into two groups depending on the conditioning regimen, ie, group A (n=15) which received cyclophosphamide (median dose of 120 mg/kg; range 100 to 200 mg/kg) and group B (n=12) which did not. Ultrasound cardiograms (UCG) and signal-averaged electrocardiograms (SAECG) were recorded in the two groups both preceding and following the BSCT. There were no statistical intergroup or intragroup differences in left ventricular (LV) dimensions or contractile function. Significant (P<0.01) posttransplant increases in interventricular septal wall thickness and Ap/Ep ratio were noted in group A. Moreover, the filtered QRS duration as estimated by SAECG was prolonged (P<0.05) whereas the summated LV voltage (SV1+RV5) was reduced in the posttransplant period only in group A. These results suggest that early cyclophosphamide cardiotoxicity was characterized by LV diastolic rather than systolic dysfunction. These findings may contribute to acute hemodynamic deterioration observed after cyclophosphamide-containing conditioning chemotherapy.

Original languageEnglish
Pages (from-to)249-261
Number of pages13
Journaljapanese heart journal
Volume43
Issue number3
DOIs
Publication statusPublished - Dec 1 2002

Fingerprint

Left Ventricular Dysfunction
Stem Cell Transplantation
Cyclophosphamide
Blood Cells
Electrocardiography
Drug Therapy
Hematologic Diseases
Anthracyclines
Hemodynamics
Cardiotoxicity

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Left ventricular diastolic dysfunction induced by cyclophosphamide in blood stem cell transplantation. / Mori, Tadashi; Yanagi, Nobuhito; Maruyama, Toru; Gondo, Hisashi; Okamura, Takashi; Kaji, Yoshikazu; Harada, Mine.

In: japanese heart journal, Vol. 43, No. 3, 01.12.2002, p. 249-261.

Research output: Contribution to journalArticle

Mori, Tadashi ; Yanagi, Nobuhito ; Maruyama, Toru ; Gondo, Hisashi ; Okamura, Takashi ; Kaji, Yoshikazu ; Harada, Mine. / Left ventricular diastolic dysfunction induced by cyclophosphamide in blood stem cell transplantation. In: japanese heart journal. 2002 ; Vol. 43, No. 3. pp. 249-261.
@article{7bcca4498b004051aada8871a5a12b1b,
title = "Left ventricular diastolic dysfunction induced by cyclophosphamide in blood stem cell transplantation",
abstract = "Cardiac complications are major limiting factors regarding the success of high-dose chemotherapy supported by blood stem cell transplantation (BSCT). The cardiotoxicity of cyclophosphamide remains obscure relative to that of anthracyclines. The aim of this study was to estimate noninvasively the cardiotoxicity of cyclophosphamide administered during the pretransplant conditioning of BSCT for patients with various hematological diseases. A total of 27 consecutive patients were divided into two groups depending on the conditioning regimen, ie, group A (n=15) which received cyclophosphamide (median dose of 120 mg/kg; range 100 to 200 mg/kg) and group B (n=12) which did not. Ultrasound cardiograms (UCG) and signal-averaged electrocardiograms (SAECG) were recorded in the two groups both preceding and following the BSCT. There were no statistical intergroup or intragroup differences in left ventricular (LV) dimensions or contractile function. Significant (P<0.01) posttransplant increases in interventricular septal wall thickness and Ap/Ep ratio were noted in group A. Moreover, the filtered QRS duration as estimated by SAECG was prolonged (P<0.05) whereas the summated LV voltage (SV1+RV5) was reduced in the posttransplant period only in group A. These results suggest that early cyclophosphamide cardiotoxicity was characterized by LV diastolic rather than systolic dysfunction. These findings may contribute to acute hemodynamic deterioration observed after cyclophosphamide-containing conditioning chemotherapy.",
author = "Tadashi Mori and Nobuhito Yanagi and Toru Maruyama and Hisashi Gondo and Takashi Okamura and Yoshikazu Kaji and Mine Harada",
year = "2002",
month = "12",
day = "1",
doi = "10.1536/jhj.43.249",
language = "English",
volume = "43",
pages = "249--261",
journal = "International Heart Journal",
issn = "1349-2365",
publisher = "International Heart Journal Association",
number = "3",

}

TY - JOUR

T1 - Left ventricular diastolic dysfunction induced by cyclophosphamide in blood stem cell transplantation

AU - Mori, Tadashi

AU - Yanagi, Nobuhito

AU - Maruyama, Toru

AU - Gondo, Hisashi

AU - Okamura, Takashi

AU - Kaji, Yoshikazu

AU - Harada, Mine

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Cardiac complications are major limiting factors regarding the success of high-dose chemotherapy supported by blood stem cell transplantation (BSCT). The cardiotoxicity of cyclophosphamide remains obscure relative to that of anthracyclines. The aim of this study was to estimate noninvasively the cardiotoxicity of cyclophosphamide administered during the pretransplant conditioning of BSCT for patients with various hematological diseases. A total of 27 consecutive patients were divided into two groups depending on the conditioning regimen, ie, group A (n=15) which received cyclophosphamide (median dose of 120 mg/kg; range 100 to 200 mg/kg) and group B (n=12) which did not. Ultrasound cardiograms (UCG) and signal-averaged electrocardiograms (SAECG) were recorded in the two groups both preceding and following the BSCT. There were no statistical intergroup or intragroup differences in left ventricular (LV) dimensions or contractile function. Significant (P<0.01) posttransplant increases in interventricular septal wall thickness and Ap/Ep ratio were noted in group A. Moreover, the filtered QRS duration as estimated by SAECG was prolonged (P<0.05) whereas the summated LV voltage (SV1+RV5) was reduced in the posttransplant period only in group A. These results suggest that early cyclophosphamide cardiotoxicity was characterized by LV diastolic rather than systolic dysfunction. These findings may contribute to acute hemodynamic deterioration observed after cyclophosphamide-containing conditioning chemotherapy.

AB - Cardiac complications are major limiting factors regarding the success of high-dose chemotherapy supported by blood stem cell transplantation (BSCT). The cardiotoxicity of cyclophosphamide remains obscure relative to that of anthracyclines. The aim of this study was to estimate noninvasively the cardiotoxicity of cyclophosphamide administered during the pretransplant conditioning of BSCT for patients with various hematological diseases. A total of 27 consecutive patients were divided into two groups depending on the conditioning regimen, ie, group A (n=15) which received cyclophosphamide (median dose of 120 mg/kg; range 100 to 200 mg/kg) and group B (n=12) which did not. Ultrasound cardiograms (UCG) and signal-averaged electrocardiograms (SAECG) were recorded in the two groups both preceding and following the BSCT. There were no statistical intergroup or intragroup differences in left ventricular (LV) dimensions or contractile function. Significant (P<0.01) posttransplant increases in interventricular septal wall thickness and Ap/Ep ratio were noted in group A. Moreover, the filtered QRS duration as estimated by SAECG was prolonged (P<0.05) whereas the summated LV voltage (SV1+RV5) was reduced in the posttransplant period only in group A. These results suggest that early cyclophosphamide cardiotoxicity was characterized by LV diastolic rather than systolic dysfunction. These findings may contribute to acute hemodynamic deterioration observed after cyclophosphamide-containing conditioning chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0036559477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036559477&partnerID=8YFLogxK

U2 - 10.1536/jhj.43.249

DO - 10.1536/jhj.43.249

M3 - Article

VL - 43

SP - 249

EP - 261

JO - International Heart Journal

JF - International Heart Journal

SN - 1349-2365

IS - 3

ER -